181 related articles for article (PubMed ID: 17505558)
1. Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes.
Castaneda F; Burse A; Boland W; Kinne RK
Int J Med Sci; 2007 May; 4(3):131-9. PubMed ID: 17505558
[TBL] [Abstract][Full Text] [Related]
2. Structural selectivity of human SGLT inhibitors.
Hummel CS; Lu C; Liu J; Ghezzi C; Hirayama BA; Loo DD; Kepe V; Barrio JR; Wright EM
Am J Physiol Cell Physiol; 2012 Jan; 302(2):C373-82. PubMed ID: 21940664
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
Pajor AM; Randolph KM; Kerner SA; Smith CD
J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Takasu T; Yokono M; Tahara A; Takakura S
Biol Pharm Bull; 2019; 42(3):507-511. PubMed ID: 30828082
[TBL] [Abstract][Full Text] [Related]
6. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.
Hummel CS; Lu C; Loo DD; Hirayama BA; Voss AA; Wright EM
Am J Physiol Cell Physiol; 2011 Jan; 300(1):C14-21. PubMed ID: 20980548
[TBL] [Abstract][Full Text] [Related]
7. Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus.
Vaidya HB; Goyal RK
Mini Rev Med Chem; 2010 Sep; 10(10):905-13. PubMed ID: 21034414
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase-A affects sorting and conformation of the sodium-dependent glucose co-transporter SGLT1.
Subramanian S; Glitz P; Kipp H; Kinne RK; Castaneda F
J Cell Biochem; 2009 Feb; 106(3):444-52. PubMed ID: 19115253
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Structure-Activity Relationship of C-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors.
Kuroda S; Kobashi Y; Kawamura M; Kawabe K; Shiozawa F; Hamada M; Shimizu Y; Okumura-Kitajima L; Koretsune H; Kimura K; Yamamoto K; Kakinuma H
Chem Pharm Bull (Tokyo); 2020; 68(7):635-652. PubMed ID: 32611999
[TBL] [Abstract][Full Text] [Related]
11. A 96-well automated method to study inhibitors of human sodium-dependent D-glucose transport.
Castaneda F; Kinne RK
Mol Cell Biochem; 2005 Dec; 280(1-2):91-8. PubMed ID: 16311909
[TBL] [Abstract][Full Text] [Related]
12. Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.
Vrhovac I; Balen Eror D; Klessen D; Burger C; Breljak D; Kraus O; Radović N; Jadrijević S; Aleksic I; Walles T; Sauvant C; Sabolić I; Koepsell H
Pflugers Arch; 2015 Sep; 467(9):1881-98. PubMed ID: 25304002
[TBL] [Abstract][Full Text] [Related]
13. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Song P; Onishi A; Koepsell H; Vallon V
Expert Opin Ther Targets; 2016 Sep; 20(9):1109-25. PubMed ID: 26998950
[TBL] [Abstract][Full Text] [Related]
14. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors.
Xu G; Gaul MD; Kuo GH; Du F; Xu JZ; Wallace N; Hinke S; Kirchner T; Silva J; Huebert ND; Lee S; Murray W; Liang Y; Demarest K
Bioorg Med Chem Lett; 2018 Nov; 28(21):3446-3453. PubMed ID: 30268701
[TBL] [Abstract][Full Text] [Related]
16. SGLT1 inhibition: Pros and cons.
Tsimihodimos V; Filippas-Ntekouan S; Elisaf M
Eur J Pharmacol; 2018 Nov; 838():153-156. PubMed ID: 30240793
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
[TBL] [Abstract][Full Text] [Related]
18. Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.
Goodwin NC; Ding ZM; Harrison BA; Strobel ED; Harris AL; Smith M; Thompson AY; Xiong W; Mseeh F; Bruce DJ; Diaz D; Gopinathan S; Li L; O'Neill E; Thiel M; Wilson AG; Carson KG; Powell DR; Rawlins DB
J Med Chem; 2017 Jan; 60(2):710-721. PubMed ID: 28045524
[TBL] [Abstract][Full Text] [Related]
19. High-yield functional expression of human sodium/d-glucose cotransporter1 in Pichia pastoris and characterization of ligand-induced conformational changes as studied by tryptophan fluorescence.
Tyagi NK; Goyal P; Kumar A; Pandey D; Siess W; Kinne RK
Biochemistry; 2005 Nov; 44(47):15514-24. PubMed ID: 16300400
[TBL] [Abstract][Full Text] [Related]
20. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
